Project Details
Description
MT2023-42: A Phase 1 Study of FT819 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
| Status | Active |
|---|---|
| Effective start/end date | 2/22/24 → 2/21/41 |
Funding
- FATE THERAPEUTICS, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.